指南与共识湿疹皮炎与荨麻疹

北欧跨学科专家共识:特应性皮炎在备孕、妊娠及哺乳期的系统抗炎治疗

Systemic anti-inflammatory treatment of atopic dermatitis during conception, pregnancy and breastfeeding: Interdisciplinary expert consensus in Northern Europe.
指南 / 共识 · J Eur Acad Dermatol Venereol · 2023-10-11

推荐环孢素A为女性备孕、妊娠及哺乳期首选长期系统治疗,短期泼尼松龙用于控制急性发作;哺乳期可选用度普利尤单抗和硫唑嘌呤;JAK抑制剂、甲氨蝶呤和霉酚酸酯应避免使用。

要点

  • 环孢素A为女性备孕、妊娠及哺乳期首选长期系统治疗,短期泼尼松龙用于控制急性发作。
  • 哺乳期度普利尤单抗和硫唑嘌呤被认为适用;备孕或妊娠期二线系统治疗未达成共识。
  • JAK抑制剂、甲氨蝶呤和霉酚酸酯在女性备孕、妊娠及哺乳期应避免,需按药物特定洗脱期处理。

核心结论

  • 该共识为育龄期特应性皮炎患者的系统抗炎治疗提供跨学科临床指导,涵盖备孕、妊娠及哺乳期。

主要发现

  • 32条声明达成完全共识,4条部分共识,4条无共识。
  • 女性备孕、妊娠及哺乳期首选环孢素A作为长期系统治疗,短期泼尼松龙用于控制急性发作。
  • 哺乳期度普利尤单抗和硫唑嘌呤被认为适用;备孕或妊娠期二线系统治疗未达成共识。
  • 男性备孕:环孢素A、硫唑嘌呤、度普利尤单抗和糖皮质激素适用;甲氨蝶呤和霉酚酸酯建议提前3个月洗脱;JAK抑制剂未达成共识。

关键数值与推荐

  • 环孢素A为女性备孕、妊娠及哺乳期首选长期系统AD治疗,短期泼尼松龙用于控制急性发作。
  • 哺乳期度普利尤单抗和硫唑嘌呤被认为适用。
  • JAK抑制剂、甲氨蝶呤和霉酚酸酯在女性备孕、妊娠及哺乳期应避免,需按药物特定洗脱期处理。
  • 男性备孕:环孢素A、硫唑嘌呤、度普利尤单抗和糖皮质激素适用;甲氨蝶呤和霉酚酸酯建议提前3个月洗脱;JAK抑制剂未达成共识。

临床怎么用

  • 该共识为照护备孕、妊娠及产后AD患者的临床医生提供跨学科临床指导。
  • 倡导并概述了AD患者跨学科管理的共享照护框架。
  • 对患者和临床医生进行妊娠期AD适当(及不适当)治疗的教育至关重要。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Treating atopic dermatitis (AD) in pregnant or breastfeeding women, and in women and men with AD aspiring to be parents is difficult and characterized by uncertainty, as evidence to inform decision-making on systemic anti-inflammatory treatment is limited. This project mapped consensus across dermatologists, obstetricians and patients in Northwestern Europe to build practical advice for managing AD with systemic anti-inflammatory treatment in men and women of reproductive age. Twenty-one individuals (sixteen dermatologists, two obstetricians and three patients) participated in a two-round Delphi process. Full consensus was reached on 32 statements, partial consensus on four statements and no consensus on four statements. Cyclosporine A was the first-choice long-term systemic AD treatment for women preconception, during pregnancy and when breastfeeding, with short-course prednisolone for flare management. No consensus was reached on second-choice systemics preconception or during pregnancy, although during breastfeeding dupilumab and azathioprine were deemed suitable. It may be appropriate to discuss continuing an existing systemic AD medication with a woman if it provides good disease control and its benefits in pregnancy outweigh its risks. Janus kinase (JAK) inhibitors, methotrexate and mycophenolate mofetil should be avoided by women during preconception, pregnancy and breastfeeding, with medication-specific washout periods advised. For men preconception: cyclosporine A, azathioprine, dupilumab and corticosteroids are appropriate; a 3-month washout prior to conception is desirable for methotrexate and mycophenolate mofetil; there was no consensus on JAK inhibitors. Patient and clinician education on appropriate (and inappropriate) AD treatments for use in pregnancy is vital. A shared-care framework for interdisciplinary management of AD patients is advocated and outlined. This consensus provides interdisciplinary clinical guidance to clinicians who care for patients with AD before, during and after pregnancy. While systemic AD medications are used uncommonly in this patient group, considerations in this article may help patients with severe refractory AD.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Deleuran M, Dézfoulian B, Elberling J, et al. Systemic anti-inflammatory treatment of atopic dermatitis during conception, pregnancy and breastfeeding: Interdisciplinary expert consensus in Northern Europe. J Eur Acad Dermatol Venereol. 2023. PMID: 37818828. doi:10.1111/jdv.19512

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。